Senate Committee Proposes Major Overhaul of Generic Drug Safety Regulations
A bipartisan group of senators on the Senate Special Committee on Aging today proposed significant changes to how the Food and Drug Administration oversees the safety and quality of generic drugs, spurred by concerns over imported medications and potential risks to public health.
The recommendations follow a recent investigation revealing that since 2013, the FDA has allowed over 20 overseas factories – primarily located in India – with documented safety and quality issues to continue shipping drugs to the United States, even after being banned from doing so. The committee criticized the agency for failing to inform Congress about this practice, calling it a “failure on the FDA’s part to protect public health.” Senator Rick Scott, R-Fla., the committee chair, stated, “The United States’ overreliance on foreign-made generic drugs, especially those made in adversarial nations, is a very real threat to all Americans, but especially our aging population.”
The senators are calling for increased testing of generic drugs, shifting away from reliance on manufacturer assurances, and greater transparency regarding the origin of medications. They also suggest leveraging the federal government’s purchasing power – as the largest drug purchaser in the U.S. – to prioritize drugs manufactured domestically, potentially through a “federal buyer’s market” launched with the Department of Defense. A recent study by Ohio State University found that generic drugs made in India were linked to more hospitalizations and adverse events than those manufactured in the United States, highlighting the potential consequences of relying on foreign suppliers. You can learn more about drug safety regulations on the FDA website.
The 34-page report also proposes requiring manufacturers to disclose the country of origin for both the drug and its key ingredients on product labels. Senator Kirsten Gillibrand, D-N.Y., emphasized that “In the richest country in the world, our constituents shouldn’t have to worry about the safety and availability of the drugs they need to fight devastating diseases.” The FDA has previously stated that exemptions were granted to prevent drug shortages and that manufacturers were required to conduct additional quality testing.
The senators have requested a briefing from Health and Human Services Secretary Robert F. Kennedy Jr. regarding the drug supply chain and potential shortages, and are awaiting a response from the agency.
